导师姓名： 李华婷 专业代码： 100201
性别： 女 专业名称： 内科学
培养单位： 附属第六人民医院 三级学科/
专业领域： 内分泌与代谢病
导师类型： 博士生导师 专业学位导师： 兼
联系方式： huarting99@sjtu.edu.cn
邮编： 200233 邮箱地址： huarting99@sjtu.edu.cn

研究方向 (点击浏览详细信息)
糖尿病及代谢相关疾病分子机制与干预研究

社会任职
Clinical Science编委

科研项目 项目编号项目名称课题来源起止年月批准经费承担职责
** 糖尿病发病机制与诊疗新靶点 国家自然科学基金优秀青年科学基金 2021-01~2023-12 120万元 课题负责人
** 成纤维细胞生长因子21在运动调节血管周围脂肪组织功能中的作用机制研究 国家自然科学基金面上项目 2019-01~2022-12 57万元 课题负责人
/ 上海市临床重点专科建设项目 ——内分泌代谢科（“振龙头”类） 上海市卫计委 2018-01~2020-12 2129.19万元 子课题负责人
17PJ** 成纤维细胞生长因子21在能量代谢适应性反应中的生理作用与分子机制 上海市浦江人才计划 2017-07~2019-06 20万元 课题负责人
2017YQ009 成纤维细胞生长因子21在能量代谢适应性反应中的作用与机制研究 上海市卫生系统优秀青年人才培养计划 2017-07~2020-06 30万元 课题负责人
2017ZZ01013 上海市重中之重临床医学中心和重点学科建设计划 上海市卫计委 2017-06~2021-05 1500万元 子课题负责人
采用生物标志物对2型糖尿病进行风险预测和转归评价的中澳联合转化研究 国家自然科学基金国际(地区)合作与交流项目 2016-01~2020-12 350万元 课题参与人
XJ** 糖尿病相关血管病变的跨学科研究: 从分子机制到干预治疗 香江****计划 2014-03~2016-02 54万元 课题负责人
13CG11 成纤维细胞生长因子21参与非酒精性脂肪肝的病理生理机制和预警价值研究 上海市教委晨光计划 2014-01~2016-12 6万元 课题负责人
13QA** 成纤维细胞生长因子21 在非酒精性脂肪肝发生发展中的分子机制和临床研究 上海市科委青年科技启明星计划 2013-07~2015-06 20万元 课题负责人
** 成纤维细胞生长因子21 在急性肝损伤中变化的机制和作用研究 国家自然科学基金青年项目 2013-01~2015-12 23万元 课题负责人

学术论文 作者论文标题期刊名出版年卷期页码
Huating Li, Guangyu Wu, Qichen Fang, Mingliang Zhang, Xiaoyan Hui, Bin Sheng, Liang Wu, Yuqian Bao, Peng Li, Aimin Xu, Weiping Jia Fibroblast growth factor 21 increases insulin sensitivity through specific expansion of subcutaneous fat. Nature Communications 2018 9(1):272
Dai L, Fang R, Li H （共同第一作者）, Hou X, Sheng B, Wu Q, Jia W Clinical Report Guided Retinal Microaneurysm Detection With Multi-Sieving Deep Learning IEEE Trans Med Imaging 2018 37(5):1149-1161
Wu L, Pan Q, Wu G, Qian L, Zhang J, Zhang L, Fang Q, Zang G, Wang Y, Lau G, Li H （通讯作者）, Jia W. Diverse Changes of Circulating Fibroblast Growth Factor 21 Levels in Hepatitis B Virus-Related Diseases. Scientific Reports 2017 ?7(1): 16482
Yin B, Li H （共同第一作者）, Sheng B, Hou X, Chen Y, Wu W, Li P, Shen R, Bao Y, Jia W Vessel extraction from non-fluorescein fundus images using orientation-aware detector. Med Image Anal 2015 26(1):232-42.
Jianxin Dou, Huating Li （共同第一作者）, Xiaojing Ma, Mingliang Zhang, Qichen Fang, Meiyun Nie, Yuqian Bao* and Weiping Jia, Jianxin Dou, Huating Li, Xiaojing Ma, Mingliang Zhang, Qichen Fang, Meiyun Nie, Yuqian Bao* and Weiping Jia, Cardiovasc Diabetol 2014 13: p. 74.
Guangyu Wu, Huating Li, Mi Zhou, Qichen Fang, Yuqian Bao, Aimin Xu, and Weiping Jia Mechanism and clinical evidence of lipocalin-2 and adipocyte fatty acid-binding protein linking obesity and atherosclerosis. Diabetes Metab Res Rev 2014 30(6): p. 447-56
Guangyu Wu, Huating Li （共同第一作者）, Qichen Fang, Shan Jiang, Lei Zhang, Jing Zhang, Xuhong Hou, Junxi Lu, Yuqian Bao, Aimin Xu, and Weiping Jia Elevated circulating lipocalin-2 levels independently predict incident cardiovascular events in men in a population-based cohort. Arterioscler Thromb Vasc Biol 2014 34(11): p. 2457-64
Dewei Ye, Yudong Wang, Huating Li, Weiping Jia, Kwan Man, Chung Mau Lo, Yu Wang, Karen S.L. Lam, and Aimin Xu Fibroblast growth factor 21 protects against acetaminophen-induced hepatotoxicity by potentiating peroxisome proliferator-activated receptor coactivator protein-1alpha-mediated antioxidant capacity in mice. Hepatology 2014 60(3): p. 977-89
Qichen Fang, Wenjing Yang, Huating Li, Wenxiu Hu, Lihui Chen, Shan Jiang, Kun Dong, Qianqian Song, Chen Wang, Shuo Chen, Feng Liu, Weiping Jia Negative Regulation of DsbA-L Gene Expression by the Transcription Factor Sp1. Diabetes 2014 63(12): p. 4165-71
Huating Li, Kun Dong, Qichen Fang, Xuhong Hou, Mi Zhou, Yuqian Bao, Kunsan Xiang, Aimin Xu, Weiping Jia High serum level of fibroblast growth factor 21 is an independent predictor of non-alcoholic fatty liver disease: A 3-year prospective study in China. J Hepatol 2013 58(3):557-63
Huating Li, Jing Zhang, Weiping Jia Fibroblast growth factor 21: a novel metabolic regulator from pharmacology to physiology Front Med. 2013 7(1):25-30
Qichen Fang, Huating Li （共同第一作者）, Qianqian Song, Wenjing Yang, Xuhong Hou, Xiaojing Ma, Junxi Lu, Aimin Xu, Weiping Jia Serum fibroblast growth factor 19 levels are decreased in Chinese subjects with impaired fasting glucose and inversely associated with fasting plasma glucose levels. Diabetes Care 2013 36(9):2810-4
Huating Li, Zhanguo Gao, Jin Zhang, Xin Ye, Aimin Xu, Jianping Ye, Weiping Jia Sodium butyrate stimulates expression of fibroblast growth factor 21 in liver by inhibition of histone deacetylase 3 Diabetes 2012 61(4):797-806
Dewei Ye, Francois Y.L. Li, Karen S.L. Lam, Huating Li, Weiping Jia, Yu Wang, Kwan Man, Chung Mau Lo, Xiaokun Li, Aimin Xu Toll-like receptor-4 mediates obesity-induced non-alcoholic steatohepatitis through activation of X-box binding protein-1 in mice Gut 2012 61(7):1058-1067
Huating Li, Qichen Fang, Fei Gao, Jia Fan, Jian Zhou, Xiaoying Wang, Xiaoping Pan, Yuqian Bao, Kunsan Xiang, Aimin Xu, Weiping Jia Fibroblast growth factor 21 levels are increased in nonalcoholic fatty liver disease patients and are correlated with hepatic triglyceride. J Hepatol 2010 53(5):934-40
Yuqian Bao, Xiaojing Ma, Huating Li, Mi Zhou, Cheng Hu, Junling Tang, Kunsan Xiang, Weiping Jia Glycated haemoglobin A1c for diagnosing diabetes in Chinese population: cross sectional epidemiological survey. BMJ 2010 340:c2249
Huating Li, Yuqian Bao, Aimin Xu, Xiaoping Pan, Junxi Lu, Haiya Wu, Huijuan Lu, Kunsan Xiang, Weiping Jia Serum Fibroblast Growth Factor 21 is Associated with Adverse Lipid Profiles and γ-glutamyltransferase but not Insulin Sensitivity in Chinese Subjects with and without Impaired Glucose Regulation. J Clin Endocrinol Metab 2009 94(6):2151-6
Yuqian Bao, Junxi Lu, Cheng Wang, Ming Yang, Huating Li, Xiaoyan Zhang, Jiehua Zhu, Huijuan Lu, Weiping Jia, Kunsan Xiang. Optimal waist circumference cutoffs for abdominal obesity in Chinese Atherosclerosis 2008 201(2):378-84